secwatch.observer — SEC 8-K summary
======================================

Issuer:     Centessa Pharmaceuticals plc (CNTA)
CIK:        0001847903
Form:       8-K
Filed at:   2026-02-13T23:59:59+00:00
Accession:  0001193125-26-051424
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Centessa finalizes advisory and separation pacts with former CEO Saha
---------------------------------------------------------------------

- Saurabh Saha stepped down as CEO on Jan 1, 2026; advisory agreement signed Feb 9, 2026.
- Advisory fee of $376/hour for initial six-month term, renewable automatically.
- Separation provides vesting of equity through Feb 2, 2026; later equity forfeited.
- Subject to Compensation Committee approval, Saha eligible for 100% of 2025 target bonus.
- Vested equity exercise window extends to three months after advisory agreement ends.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847903/000119312526051424/0001193125-26-051424-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847903/000119312526051424/d932267d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-051424

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer